After the expected detectable cancers that arose in subjects with PSA < 4 ng/ml were taken into account, the sensitivity and specificity for the PSA cutoff at 4 ng/ml were reduced to 55.4% and 94.3%, respectively (Table 4). This evidence concerns the gene KLK3 and cancer.